Search results
Showing 8881 to 8895 of 8905 results
Children and young people set to benefit from new treatment for peanut allergy
Children and young people aged between 4 and 17 with a peanut allergy could benefit from Palforzia, a new treatment which can help build up their tolerance to peanut.
Putting user needs at the heart of an advisory service for AI and data-driven technologies
Toni Gasse explains how user-needs are being placed front and centre to develop a multi-agency advisory service for artificial intelligence and data-driven technologies.
Patients in England with severe beta-thalassaemia will be amongst the first in Europe to benefit from one-time gene therapy exagamglogene autotemcel.
14,000 women at risk of fractures after the menopause to benefit from bone disease drug
Over 14,000 people to benefit after NICE published final guidance recommending abaloparatide as an option for treating osteoporosis after menopause, if there is a very high risk of fracture.
Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE to recommend Enhertu as cost effective for the NHS in final guidance published today.
People at risk of severe COVID-19 to have access to antiviral Paxlovid
A further 1.4 million people who have an increased risk for progression to severe COVID-19 will be eligible for Paxlovid if they test positive.
A new treatment option given with chemotherapy is recommended for some types of advanced or recurrent womb cancer in final draft NICE guidance published today.
NICE publishes final draft guidance on Enhertu after commercial discussions conclude
NICE does not recommend Enhertu (also called trastuzumab deruxtecan and made by Daiichi Sankyo) for treating advanced HER2-low breast cancer in adults.
25,000 people to benefit after NICE recommends new ulcerative colitis treatment
New one-a-day pill recommended on the same day the treatment was granted a licence by the MHRA.
Thousands of people asked each year could be missing out on brief interventions to help curb problem drinking, or a potential referral to specialist alcohol services.
People with triple negative breast cancer that has spread to other parts of the body may soon benefit from pembrolizumab in combination with chemotherapy.
How my experience as a patient helped shape NICE guidelines for colorectal cancer
Following my surgery and treatment for colorectal cancer in 2014, I wanted to contribute to research in the cancer field and hopefully improve things for patients in the future.
A 'safe space' for addressing complex health technology assessment challenges
Nick Crabb discusses how we’re developing a collaborative space for research and development, to help us create new methods and processes for health technology assessment.
NICE recommends several treatment options to help with rheumatoid arthritis
Around 25,000 people with moderate rheumatoid arthritis that has not responded to conventional therapies are set to benefit from the recommendations announced today.
Change in treatment for people with early breast cancer to benefit around 4,000
Around 4,000 people are set to benefit from a change in treatment for early breast cancer following provisional approval by NICE of abemaciclib in combination with hormone therapy.